|
View this as a webpage
Minnesota Department of Health
February 15, 2022
On Feb. 11, the Centers for Disease Control and Prevention (CDC) updated their Interim Clinical Considerations for Use of COVID-19 Vaccines. Along with the updates below, the clinical considerations have been reorganized and many sections have been condensed.
People who are moderately or severely immunocompromised
- Clarification of existing recommendation to receive a 3-dose mRNA vaccine primary series followed by a booster dose for a total of 4 doses.
- New guidance to shorten the interval between completion of the mRNA vaccine primary series and the booster dose to at least 3 months (instead of 5 months).
- Refer to Table 3 for a summary of the updated COVID-19 vaccination schedule for people who are immunocompromised.
- New guidance for those who received the Janssen (Johnson & Johnson) COVID-19 vaccine primary series to receive an additional dose and a booster dose, for a total of 3 doses to be up to date.
- Refer to Appendix B for additional information about completing schedules that have included the use of the Janssen COVID-19 vaccine in this population.
People who received monoclonal antibodies or convalescent plasma
- COVID-19 vaccination can be given at any time following receipt of antibody products as part of COVID-19 treatment, post-exposure prophylaxis, or pre-exposure prophylaxis. Deferral periods for vaccination have been eliminated.
People who received COVID-19 vaccine outside the United States
- Updated guidance on receiving a booster dose. Refer to Appendix E for additional details.
People with a history of myocarditis or pericarditis after an mRNA COVID-19 vaccine
We are updating MDH vaccine protocols, screening and agreement form, and provider guide with these recent changes and the updated resources will be posted on COVID-19 Vaccine Providers soon.
Providing an additional dose as part of the primary series followed by a booster dose for people who are moderately to severely immunocompromised is shown to provide improved protection against SARS-CoV-2 infection and hospitalization. Ensure you are administering all current recommended doses to keep them up to date.
People can self-attest to their moderately to severely immunocompromised status and receive COVID-19 vaccine doses wherever vaccines are offered. Vaccinators should not deny COVID-19 vaccination to a person due to lack of documentation.
Vaccinated people who are immunocompromised should be counseled about the potential for a reduced immune response to COVID-19 vaccines. They and their close contacts should continue to follow current prevention measures on CDC: How to Protect Yourself & Others.
|
